<p>Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 獲取免費報告）目前被覆蓋的十三位分析師給予了 “買入” 的平均推薦，MarketBeat.com 報道。一位研究分析師對該股票給予了賣出推薦，十位分析師給予了買入推薦，另外兩位給予了強烈買入推薦。在過去一年中更新了對該股票覆蓋的經紀人中，平均一年目標價為 $11.6364。</p>
<p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
<p>幾位股票研究分析師對 TSHA 股票發佈了報告。Canaccord Genuity Group 將 Taysha Gene Therapies 的目標價從 $14.00 上調至 $17.00，並在 4 月 6 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在週六的研究報告中將 Taysha Gene Therapies 的評級從 “持有” 下調至 “賣出”。Needham &amp; Company LLC 在 3 月 19 日的研究報告中將 Taysha Gene Therapies 的目標價從 $10.00 上調至 $12.00，並給予該公司 “買入” 評級。Chardan Capital 在 3 月 19 日的研究報告中重新發布了 “買入” 評級，並對 Taysha Gene Therapies 的股票設定了 $12.00 的目標價。最後，Truist Financial 在 3 月 25 日的研究報告中將 Taysha Gene Therapies 的評級提升至 “強烈買入”。</p>
<p><strong>查看我們對 TSHA 的最新股票分析</strong></p>
<h2>Taysha Gene Therapies 的內部買賣</h2>
<ul>
<li>3 只小盤股供您秋季購物清單參考</li>
</ul>
<p>在其他新聞中，內部人士 Sukumar Nagendran 於 4 月 10 日星期五出售了該公司 200,000 股股票。股票的平均售價為 $4.46，總價值為 $892,000.00。出售完成後，內部人士持有該公司 1,136,410 股股票，估值約為 $5,068,388.60。這代表其持股減少了 14.97%。該交易在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士持有該公司 3.78% 的股份。</p>
<h2>機構投資者對 Taysha Gene Therapies 的看法</h2>
<p>幾家對沖基金最近調整了對 TSHA 的持股。Marex Group plc 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約 $29,000。E Fund Management Co. Ltd. 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約 $31,000。Arrowpoint Investment Partners Singapore Pte. Ltd. 在第三季度購買了 Taysha Gene Therapies 的新股份，價值約 $40,000。Tower Research Capital LLC TRC 在第二季度將其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 現在擁有該公司 17,606 股股票，價值 $41,000，此前在此期間又購買了 10,742 股。最後，Caitong International Asset Management Co. Ltd 在第四季度將其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 現在擁有該公司 7,811 股股票，價值 $43,000，此前在此期間又購買了 4,607 股。對沖基金和其他機構投資者持有該公司 77.70% 的股份。</p>
<h2>Taysha Gene Therapies 的價格表現</h2>
<p>Taysha Gene Therapies 股票在週五開盤價為 $6.81。該股票的市值為 $19.6 億，市盈率為 -17.92，貝塔值為 1.25。該公司的債務與股本比率為 0.20，流動比率為 12.23，速動比率為 12.23。Taysha Gene Therapies 的一年低點為 $2.06，一年高點為 $7.30。該公司的 50 日移動平均線為 $5.07，200 日移動平均線為 $4.93。</p>
<p>Taysha Gene Therapies（NASDAQ:TSHA - 獲取免費報告）最後一次發佈季度財報是在 5 月 6 日星期三。該公司報告每股收益（EPS）為 ($0.12)，低於市場共識預期的 ($0.10) 低了 ($0.02)。研究分析師平均預測 Taysha Gene Therapies 在本年度將發佈 -0.44 的每股收益。</p>
<h2>關於 Taysha Gene Therapies</h2>
<p>（獲取免費報告）</p>
<p>Taysha Gene Therapies, Inc NASDAQ: TSHA 是一家臨牀階段的生物技術公司，專注於開發針對中樞神經系統罕見單基因疾病的基因療法。該公司使用專有的腺病毒相關病毒（AAV）載體平台，設計新型的衣殼和調控元件，以優化治療基因的遞送和表達。其產品管線包括針對 GM2 神經節苷脂症（Tay–Sachs 和 Sandhoff 疾病）的 TSHA-102、針對 GM1 神經節苷脂症的 TSHA-101，以及針對芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及其他針對危及生命的兒童中樞神經系統疾病的早期候選藥物。</p>
<p>Taysha Gene Therapies 成立於 2019 年，總部位於德克薩斯州達拉斯，於 2021 年 5 月完成首次公開募股。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Taysha Gene Therapies</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 $1,000 在 Taysha Gene Therapies 嗎？</h2>
<p>在您考慮 Taysha Gene Therapies 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
<p>雖然 Taysha Gene Therapies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TSHA

紐交所高增長板生物技術指數 ETF - First Trust

基因改革 ETF - ARK

<p>Taysha Gene Therapies, Inc.（納斯達克代碼：TSHA）獲得了十三位分析師的平均 “買入” 推薦。一位分析師將其評為賣出，十位分析師評為買入，另外兩位評為強力買入。平均一年目標價為 11.64 美元。最近的報告顯示，Canaccord Genuity 和 Needham & Company 上調了目標價。內部人士 Sukumar Nagendran 出售了 200,000 股，減少了 14.97% 的持股比例。機構投資者持有 77.70% 的股份。TSHA 開盤價為 6.81 美元，市值為 19.6 億美元，過去一年價格區間為 2.06 美元至 7.30 美元</p>

<p>Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has been assigned an average recommendation of &#34;Buy&#34; from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $11.6364.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc.（NASDAQ:TSHA - 獲取免費報告）目前被覆蓋的十三位分析師給予了 “買入” 的平均推薦，MarketBeat.com 報道。一位研究分析師對該股票給予了賣出推薦，十位分析師給予了買入推薦，另外兩位給予了強烈買入推薦。在過去一年中更新了對該股票覆蓋的經紀人中，平均一年目標價為 $11.6364。</p>
</div><p>Get <strong>Taysha Gene Therapies</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Taysha Gene Therapies</strong> 的提醒：</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物技術公司還有希望嗎？</li>
</ul>
</div><p>Several equities research analysts have issued reports on TSHA shares. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 6th. Wall Street Zen cut shares of Taysha Gene Therapies from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Needham &amp; Company LLC boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, March 19th. Chardan Capital reissued a &#34;buy&#34; rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Truist Financial raised shares of Taysha Gene Therapies to a &#34;strong-buy&#34; rating in a research report on Wednesday, March 25th.</p>
<div class="lb-trans"><p>幾位股票研究分析師對 TSHA 股票發佈了報告。Canaccord Genuity Group 將 Taysha Gene Therapies 的目標價從 $14.00 上調至 $17.00，並在 4 月 6 日的研究報告中給予該公司 “買入” 評級。Wall Street Zen 在週六的研究報告中將 Taysha Gene Therapies 的評級從 “持有” 下調至 “賣出”。Needham &amp; Company LLC 在 3 月 19 日的研究報告中將 Taysha Gene Therapies 的目標價從 $10.00 上調至 $12.00，並給予該公司 “買入” 評級。Chardan Capital 在 3 月 19 日的研究報告中重新發布了 “買入” 評級，並對 Taysha Gene Therapies 的股票設定了 $12.00 的目標價。最後，Truist Financial 在 3 月 25 日的研究報告中將 Taysha Gene Therapies 的評級提升至 “強烈買入”。</p>
</div><p><strong>View Our Latest Stock Analysis on TSHA</strong></p>
<div class="lb-trans"><p><strong>查看我們對 TSHA 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的內部買賣</h2>
</div><ul>
<li>3 Small-Cap Stocks For Your Fall Shopping List</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股供您秋季購物清單參考</li>
</ul>
</div><p>In other news, insider Sukumar Nagendran sold 200,000 shares of the company's stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company's stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Sukumar Nagendran 於 4 月 10 日星期五出售了該公司 200,000 股股票。股票的平均售價為 $4.46，總價值為 $892,000.00。出售完成後，內部人士持有該公司 1,136,410 股股票，估值約為 $5,068,388.60。這代表其持股減少了 14.97%。該交易在向證券交易委員會提交的文件中披露，您可以通過此鏈接訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士持有該公司 3.78% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>機構投資者對 Taysha Gene Therapies 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of TSHA. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth approximately $40,000. Tower Research Capital LLC TRC lifted its position in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company's stock worth $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd lifted its position in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company's stock worth $43,000 after purchasing an additional 4,607 shares during the period. Hedge funds and other institutional investors own 77.70% of the company's stock.</p>
<div class="lb-trans"><p>幾家對沖基金最近調整了對 TSHA 的持股。Marex Group plc 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約 $29,000。E Fund Management Co. Ltd. 在第二季度購買了 Taysha Gene Therapies 的新股份，價值約 $31,000。Arrowpoint Investment Partners Singapore Pte. Ltd. 在第三季度購買了 Taysha Gene Therapies 的新股份，價值約 $40,000。Tower Research Capital LLC TRC 在第二季度將其在 Taysha Gene Therapies 的持股增加了 156.5%。Tower Research Capital LLC TRC 現在擁有該公司 17,606 股股票，價值 $41,000，此前在此期間又購買了 10,742 股。最後，Caitong International Asset Management Co. Ltd 在第四季度將其在 Taysha Gene Therapies 的持股增加了 143.8%。Caitong International Asset Management Co. Ltd 現在擁有該公司 7,811 股股票，價值 $43,000，此前在此期間又購買了 4,607 股。對沖基金和其他機構投資者持有該公司 77.70% 的股份。</p>
</div><h2>Taysha Gene Therapies Price Performance</h2>
<div class="lb-trans"><h2>Taysha Gene Therapies 的價格表現</h2>
</div><p>Taysha Gene Therapies stock opened at $6.81 on Friday. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -17.92 and a beta of 1.25. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. Taysha Gene Therapies has a 1 year low of $2.06 and a 1 year high of $7.30. The firm has a 50-day moving average of $5.07 and a two-hundred day moving average of $4.93.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 股票在週五開盤價為 $6.81。該股票的市值為 $19.6 億，市盈率為 -17.92，貝塔值為 1.25。該公司的債務與股本比率為 0.20，流動比率為 12.23，速動比率為 12.23。Taysha Gene Therapies 的一年低點為 $2.06，一年高點為 $7.30。該公司的 50 日移動平均線為 $5.07，200 日移動平均線為 $4.93。</p>
</div><p>Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, research analysts forecast that Taysha Gene Therapies will post -0.44 earnings per share for the current year.</p>
<div class="lb-trans"><p>Taysha Gene Therapies（NASDAQ:TSHA - 獲取免費報告）最後一次發佈季度財報是在 5 月 6 日星期三。該公司報告每股收益（EPS）為 ($0.12)，低於市場共識預期的 ($0.10) 低了 ($0.02)。研究分析師平均預測 Taysha Gene Therapies 在本年度將發佈 -0.44 的每股收益。</p>
</div><h2>About Taysha Gene Therapies</h2>
<div class="lb-trans"><h2>關於 Taysha Gene Therapies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Taysha Gene Therapies, Inc NASDAQ: TSHA is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.</p>
<div class="lb-trans"><p>Taysha Gene Therapies, Inc NASDAQ: TSHA 是一家臨牀階段的生物技術公司，專注於開發針對中樞神經系統罕見單基因疾病的基因療法。該公司使用專有的腺病毒相關病毒（AAV）載體平台，設計新型的衣殼和調控元件，以優化治療基因的遞送和表達。其產品管線包括針對 GM2 神經節苷脂症（Tay–Sachs 和 Sandhoff 疾病）的 TSHA-102、針對 GM1 神經節苷脂症的 TSHA-101，以及針對芳香 L-氨基酸脱羧酶（AADC）缺乏症的 TSHA-103，以及其他針對危及生命的兒童中樞神經系統疾病的早期候選藥物。</p>
</div><p>Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.</p>
<div class="lb-trans"><p>Taysha Gene Therapies 成立於 2019 年，總部位於德克薩斯州達拉斯，於 2021 年 5 月完成首次公開募股。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Taysha Gene Therapies</li>
<li>Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due</li>
<li>Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches</li>
<li>Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money</li>
<li>Water Infrastructure: Why This Boring Sector Could Get Exciting</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Taysha Gene Therapies</li>
<li>巴菲特花了 60 年忽視科技，賬單即將到來</li>
<li>對黃金感到興奮但不確定其走勢？試試這三種方法</li>
<li>美元處於三年低點：三家出口商悄然印鈔</li>
<li>水務基礎設施：為什麼這個乏味的行業可能會變得令人興奮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFNIQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TSHA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Taysha Gene Therapies Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 $1,000 在 Taysha Gene Therapies 嗎？</h2>
</div><p>Before you consider Taysha Gene Therapies, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Taysha Gene Therapies 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Taysha Gene Therapies 並不在名單上。</p>
</div><p>While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Taysha Gene Therapies 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages

Market Beat

Taysha Gene Therapies

標普生物技術 3 倍做多 - Direxion

2 倍做多納斯達克生物技術 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

Neurogene

Truist Financial

Marex

Taysha Gene Therapies, Inc.（納斯達克股票代碼：TSHA）被券商給予 “買入” 評級的平均推薦